Cited by 1,858HER2/EGFR in Cancer ResearchPI3K/AKT/mTOR signaling in cancerBreast Cancer Treatment Studies

The DOI matches its Crossref record; 65 of the 70 references it cites were found in a registry or an index.

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Open access

Nagata, Yoichi, Lan, Keng-Hsueh, Zhou, Xiaoyan, Tan, Ming, Esteva, Francisco J., Sahin, Aysegul A., Klos, Kristine S., Li, Ping, Monia, Brett P., Nguyen, Nina T., Hortobagyi, Gabriel N., Hung, Mien-Chie, Yu, Dihua·2004·Cancer Cell

DOI 10.1016/j.ccr.2004.06.022

Open this paper in CoChat — free account Open PDF

Abstract

The ErbB2-targeting antibody, trastuzumab (Herceptin), has remarkable therapeutic efficacy in certain patients with ErbB2-overexpressing tumors. The overall trastuzumab response rate, however, is limited and what determines trastuzumab response is poorly understood. Here we report that PTEN activation contributes to trastuzumab's antitumor activity. Trastuzumab treatment quickly increased PTEN membrane localization and phosphatase activity by reducing PTEN tyrosine phosphorylation via Src inhibition. Reducing PTEN in breast cancer cells by antisense oligonucleotides conferred trastuzumab resistance in vitro and in vivo. Patients with PTEN-deficient breast cancers had significantly poorer responses to trastuzumab-based therapy than those with normal PTEN. Thus, PTEN deficiency is a powerful predictor for trastuzumab resistance. Additionally, PI3K inhibitors rescued PTEN loss-induced trastuzumab resistance, suggesting that PI3K-targeting therapies could overcome this resistance.

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2004.06.022

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
Cobleigh, M., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V. E., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,767
New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway
Cantley, L. C., & Neel, B. G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4240 · Cited by 2,018
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
Cho, H., Mason, K., Ramyar, K. X., Stanley, A. M., Gabelli, S. B., Denney, D. W., & Leahy, D. J. (2003) · Nature · doi:10.1038/nature01392 · Cited by 1,637
The Multiple Roles of PTEN in Tumor Suppression
Di Cristofano, A., & Pandolfi, P. P. (2000) · Cell · doi:10.1016/s0092-8674(00)80674-1 · Cited by 1,182
Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)
Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D. D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 886

Flagged first, then by citations

Show all 70 references

5 of the 70 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Petit, 1997, Neutralizing antibodies against epidermal growth factor and ErbB2/neu receptor tyrosine kinase down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo, Am. J. Pathol., 151, 1523

Sorted by citations

Items 701–800 of 1,001

JQ1 suppresses tumor growth via PTEN/PI3K/AKT pathway in endometrial cancer
Qiu, H., Li, J., Clark, L. H., Jackson, A. L., Zhang, L., Guo, H., Kilgore, J. E., Gehrig, P. A., Zhou, C., & Bae-Jump, V. L. (2016) · Oncotarget · doi:10.18632/oncotarget.11631 · Cited by 45
Retracted
PTEN loss is associated with a poor response to trastuzumab in HER2-overexpressing gastroesophageal adenocarcinoma
Deguchi, Y., Okabe, H., Oshima, N., Hisamori, S., Minamiguchi, S., Muto, M., & Sakai, Y. (2016) · Gastric Cancer · doi:10.1007/s10120-016-0627-z · Cited by 45
Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer
Morrow, P. K. H., Zambrana, F. R., & Esteva, F. J. (2009) · Breast Cancer Research · doi:10.1186/bcr2324 · Cited by 46
EGF Prevents the Neuroendocrine Differentiation of LNCaP Cells Induced By Serum Deprivation: The Modulator Role of P13K/Akt
Orozco, R. M. M., Almaraz-Pro, C., Rodríguez‐Ubreva, J., Cortés, M. A., Ropero, S., Colomer, R., López‐Ruiz, P., & Colás, B. (2007) · Neoplasia · doi:10.1593/neo.07337 · Cited by 45
Targeting HER2 in Prostate Cancer: Where to Next?
Solit, D. B., & Rosen, N. X. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8187 · Cited by 45
Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs
Gámez-Chiachio, M., Sarrió, D., & Moreno‐Bueno, G. (2022) · Cancers · doi:10.3390/cancers14184543 · Cited by 49
PC Cell–Derived Growth Factor Stimulates Proliferation and Confers Trastuzumab Resistance to Her-2-Overexpressing Breast Cancer Cells
Kim, W. E., & Serrero, G. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2663 · Cited by 44
The Role of PTEN in Tumor Angiogenesis
Rodriguez, S., & Huynh‐Do, U. (2011) · Journal of Oncology · doi:10.1155/2012/141236 · Cited by 44
Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease
Yarden, Y., & Wheeler, D. L. (2014) · Springer eBooks · doi:10.1007/978-1-4939-2053-2 · Cited by 44
Advances in systemic therapy for metastatic breast cancer: future perspectives
Corona, S. P., Sobhani, N., Ianza, A., Roviello, G., Mustacchi, G., Bortul, M., Zanconati, F., & Generali, D. (2017) · Medical Oncology · doi:10.1007/s12032-017-0975-5 · Cited by 44
Cooperative antitumor activities of carnosic acid and Trastuzumab in ERBB2+ breast cancer cells
D’Alesio, C., Bellese, G., Gagliani, M. C., Aiello, C., Grasselli, E., Marcocci, G., Bisio, A., Tavella, S., Daniele, T., Cortese, K., et al. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0615-0 · Cited by 44
Multifunctional trastuzumab–chlorin e6 conjugate for the treatment of HER2-positive human breast cancer
Kim, K. S., Kim, J., Kim, D. H., Hwang, H. S., & Na, K. (2018) · Biomaterials Science · doi:10.1039/c7bm01084b · Cited by 44
Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells
Scotti, M. L., Langenheim, J. F., Tomblyn, S., Springs, A. E. B., & Chen, W. Y. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9789-z · Cited by 44
Insulin-Like Growth Factor-1 Receptor Signaling Increases the Invasive Potential of Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer Cells via Src-Focal Adhesion Kinase and Forkhead Box Protein M1
Sanabria-Figueroa, E., Donnelly, S., Foy, K. C., Buss, M. C., Castellino, R. C., Paplomata, E., Taliaferro-Smith, L. D., Kaumaya, P. T. P., & Nahta, R. (2014) · Molecular Pharmacology · doi:10.1124/mol.114.095380 · Cited by 46
Cancer immunoprevention
Lollini, P., Giovanni, C. D., Pannellini, T., Cavallo, F., Forni, G., & Nanni, P. (2005) · Future Oncology · doi:10.1517/14796694.1.1.57 · Cited by 44
Checks and balances: Interplay of RTKs and PTPs in cancer progression
Sastry, S. K., & Elferink, L. A. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.06.016 · Cited by 43
Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer
Wang, Q., Li, S.-H., Wang, H., Xiao, Y. Q., Şahin, Ö., Brady, S. W., Li, P., Ge, H., Jaffee, E. M., Muller, W. J., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1339-t · Cited by 45
Advances in Molecular and Clinical Subtyping of Breast Cancer and Their Implications for Therapy
Cadoo, K. A., Traina, T. A., & King, T. A. (2013) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2013.06.006 · Cited by 43
A Novel Bispecific Antibody against Human CD3 and Ephrin Receptor A10 for Breast Cancer Therapy
Taki, S., Kamada, H., Inoue, M., Kazuya, N., Mukai, Y., Higashisaka, K., Yoshioka, Y., Tsutsumi, Y. M., & Tsunoda, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144712 · Cited by 43
Potential Prognostic Significance of p185 HER2 Overexpression with Loss of PTEN Expression in Gastric Carcinomas
lm, S.-A., Lee, K. E., Nam, E., Kim, D. Y., Lee, J., Han, H., Seoh, J., Park, H., Cho, M.-S., Han, W. S., et al. (2005) · Tumori Journal · doi:10.1177/030089160509100612 · Cited by 43
Protein Expression of Programmed Death 1 Ligand 1 and HER2 in Gastric Carcinoma
Oki, E., Okano, S., Saeki, H., Umemoto, Y., Teraishi, K., Nakaji, Y., Ando, K., Zaitsu, Y., Yamashita, N., Sugiyama, M., et al. (2017) · Oncology · doi:10.1159/000479231 · Cited by 43
miR‐200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancer
Tang, H., Song, C., Ye, F., Gao, G., Ou, X., Zhang, L., Xie, X., & Xie, X. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14681 · Cited by 43
Ultrasound Microbubbles Mediated Sonosensitizer and Antibody Co-delivery for Highly Efficient Synergistic Therapy on HER2-Positive Gastric Cancer
Sun, L., Zhang, J., Xu, M., Zhang, L., Tang, Q., Chen, J., Gong, M., Sun, S., Ge, H., Wang, S., et al. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c21924 · Cited by 43
A Phase II Trial with Trastuzumab and Pertuzumab in Patients with HER2-Overexpressed Locally Advanced and Metastatic Breast Cancer
Walshe, J. M., Denduluri, N., Berman, A. W., Rosing, D. R., & Swain, S. M. (2006) · Clinical Breast Cancer · doi:10.3816/cbc.2006.n.009 · Cited by 43
Pharmacodiagnostics and Targeted Therapies—A Rational Approach for Individualizing Medical Anticancer Therapy in Breast Cancer
Jørgensen, J. T., Nielsen, K. V., & Ejlertsen, B. (2007) · The Oncologist · doi:10.1634/theoncologist.12-4-397 · Cited by 43
Circumventing De Novo and Acquired Resistance to Trastuzumab: New Hope for the Care of ErbB2-Positive Breast Cancer
Piccart, M. J. (2008) · Clinical Breast Cancer · doi:10.3816/cbc.2008.s.006 · Cited by 43
NF-κB signaling in therapy resistance of breast cancer: Mechanisms, approaches, and challenges
Guo, Q. H., Jin, Y., Lin, M., Zeng, C., & Zhang, J. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122684 · Cited by 51
HER-2 as a Target for Breast Cancer Therapy
Ignatiadis, M., Desmedt, C., Sotiriou, C. P., de Azambuja, E., & Piccart, M. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1844 · Cited by 41
HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer
Boulbés, D. R., Arold, S. T., Chauhan, G. B., Blachno, K. V., Deng, N., Chang, W., Jin, Q., Huang, T.-H., Hsu, J.-M., Brady, S. W., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.10.011 · Cited by 41
Jumping higher: is it still possible? The ALTTO trial challenge
Tomasello, G., de Azambuja, E., Dinh, P., Snoj, N., & Piccart, M. J. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.12.1883 · Cited by 42
Regulation of ERBB2 Receptor by t-DARPP Mediates Trastuzumab Resistance in Human Esophageal Adenocarcinoma
Hong, J., Katsha, A. M., Lu, P., Shyr, Y., Belkhiri, A., & El-Rifai, W. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1119 · Cited by 42
PIK3CA Hotspot Mutation Scanning by a Novel and Highly Sensitive High-Resolution Small Amplicon Melting Analysis Method
Vorkas, P. A., Πουμπουρίδου, Ν., Agelaki, S., Κroupis, C., Georgoulias, V., & Lianidou, E. S. (2010) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2010.100008 · Cited by 43
HER2 testing: a review of detection methodologies and their clinical performance
Laudadio, J., Quigley, D. I., Tubbs, R., & Wolff, D. J. (2006) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.7.1.53 · Cited by 42
In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells
Ozbay, T., Durden, D. L., Liu, T., O'Regan, R. M., & Nahta, R. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1075-9 · Cited by 41
Insulin growth factor receptor‐1 expression and loss of PTEN protein predict early recurrence in triple‐negative breast cancer
Iqbal, J., Thike, A. A., Cheok, P. Y., Tse, G. M.-K., & Tan, P. H. (2012) · Histopathology · doi:10.1111/j.1365-2559.2012.04255.x · Cited by 41
Clinical activity of mammalian target of rapamycin inhibitors in solid tumors
Alvarado, Y., Mita, M. M., Vemulapalli, S., Mahalingam, D., & Mita, A. C. (2011) · Targeted Oncology · doi:10.1007/s11523-011-0178-5 · Cited by 41
Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status
Nuciforo, P. G., Aura, C. M., Holmes, E. M., Prudkin, L., Jimenez, J., Martinez, P., Ameels, H., de la Peña, L., Ellis, C., Eidtmann, H., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv175 · Cited by 41
RETRACTED ARTICLE: Dysregulated JAK2 expression by TrkC promotes metastasis potential, and EMT program of metastatic breast cancer
Kim, M. S., Jeong, J., Seo, J., Kim, H.-S., Kim, S., & Jin, W. (2016) · Scientific Reports · doi:10.1038/srep33899 · Cited by 40
Retracted
Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer
Takeda, T., Yamamoto, H., Kanzaki, H., Suzawa, K., Yoshioka, T., Tomida, S., Cui, X., Murali, R., Namba, K., Sato, H., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171356 · Cited by 42
Amplification of HER2 is a marker for global genomic instability
Ellsworth, R. E., Ellsworth, D. L., Patney, H. L., Deyarmin, B., Love, B., Hooke, J. A., & Shriver, C. D. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-297 · Cited by 41
Continued Use of Trastuzumab (Herceptin) after Progression on Prior Trastuzumab Therapy in HER-2-Positive Metastatic Breast Cancer
Pusztai, L., & Esteva, F. J. (2006) · Cancer Investigation · doi:10.1080/07357900500524629 · Cited by 41
Posttranslational Regulation and Conformational Plasticity of PTENPreprint
Kotelevets, L., Trifault, B., Chastre, E., & Scott, M. G. H. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a036095 · Cited by 40
Mammalian Target of Rapamycin as a Rational Therapeutic Target for Breast Cancer Treatment
LoRusso, P. M. (2012) · Oncology · doi:10.1159/000343063 · Cited by 43
Overcoming Treatment Resistance in HER2-Positive Breast Cancer
Puglisi, F., Minisini, A. M., Angelis, C. D., & Arpino, G. (2012) · Drugs · doi:10.2165/11634000-000000000-00000 · Cited by 41
HER2-positive breast cancer: beyond trastuzumab.
Murphy, C. G., & Fornier, M. N. (2010) · PubMed · Cited by 40
Calpain‐1 expression is associated with relapse‐free survival in breast cancer patients treated with trastuzumab following adjuvant chemotherapy
Storr, S. J., Woolston, C. M., Barros, F., Green, A. R., Shehata, M., Chan, S. Y. T., Ellis, I. O., & Martin, S. G. (2010) · International Journal of Cancer · doi:10.1002/ijc.25832 · Cited by 40
Functional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapy
Sohn, J., Do, K. A., Liu, S., Chen, H., Mills, G. B., Hortobágyi, G. N., Meric‐Bernstam, F., & Gonzalez-Angulo, A. M. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt248 · Cited by 40
Enhanced PI3K p110α Signaling Confers Acquired Lapatinib Resistance That Can Be Effectively Reversed by a p110α-Selective PI3K Inhibitor
Brady, S. W., Zhang, J., Seok, D., Wang, H., & Yu, D. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0518 · Cited by 40
Targeting Src and Tubulin in Mucinous Ovarian Carcinoma
Liu, T., Hu, W., Dalton, H. J., Choi, H. J., Huang, J., Kang, Y., Pradeep, S., Miyake, T. M., Song, J. H., Wen, Y., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1305 · Cited by 40
Autocrine Motility Factor Promotes HER2 Cleavage and Signaling in Breast Cancer Cells
Kho, D. H., Nangia‐Makker, P., Balan, V., Hogan, V. A., Tait, L. R., Wang, Y., & Raz, A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2149 · Cited by 40
ARL4C stabilized by AKT/mTOR pathway promotes the invasion of PTEN‐deficient primary human glioblastoma
Chen, Q., Weng, H., Tang, X., Lin, Y. Q., Yuan, Y., Li, Q., Tang, Z., Wu, H., Yang, S., Li, Y., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5189 · Cited by 40
G9a Promotes Breast Cancer Recurrence through Repression of a Pro-inflammatory Program
Mabe, N. W., Garcia, N. M. G., Wolery, S. E., Newcomb, R., Meingasner, R. C., Vilona, B. A., Lupo, R., Lin, C., Chi, J., & Alvarez, J. V. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108341 · Cited by 40
Resistance to Imatinib Mesylate-induced apoptosis in acute lymphoblastic leukemia is associated with PTEN down-regulation due to promoter hypermethylation
Montiel‐Duarte, C., Cordeu, L., Agirre, X., Román‐Gómez, J., Jiménez‐Velasco, A., José‐Eneriz, E. S., Gárate, L., Andreu, E. J., Calasanz, M. J., Heiniger, A., et al. (2008) · Leukemia Research · doi:10.1016/j.leukres.2007.09.005 · Cited by 40
Proteasome inhibitor bortezomib increases PTEN expression and enhances trastuzumab-induced growth inhibition in trastuzumab-resistant cells
Fujita, T., Doihara, H., Washio, K., Kawasaki, K., Takabatake, D., Takahashi, H., Tsukuda, K., Ogasawara, Y., & Shimizu, N. (2006) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000198910.90819.06 · Cited by 40
EGFR enhances Survivin expression through the phosphoinositide 3 (PI-3) kinase signaling pathway
Wang, Q., & Greene, M. I. (2005) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2005.05.002 · Cited by 40
Overcoming Resistance to Targeted Therapies in Cancer
Redmond, K. L., Papafili, A., Lawler, M., & Schaeybroeck, S. V. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.028 · Cited by 39
Optimal protocol for PTEN immunostaining; role of analytical and preanalytical variables in PTEN staining in normal and neoplastic endometrial, breast, and prostatic tissues
Maiques, Ó., Santacana, M., Valls, J., Pallarés, J., Mirantes, C., Gatius, S., Garcia-Dios, D. A., Amant, F. C., Pedersen, H. C., Dolcet, X., et al. (2013) · Human Pathology · doi:10.1016/j.humpath.2013.10.018 · Cited by 39
MicroRNA and HER2-overexpressing Cancer
Wang, S., & Lin, R.-J. (2013) · MicroRNA · doi:10.2174/22115366113029990011 · Cited by 42
Targeted Inhibition of Kinases in Cancer Therapy
Baker, S. J., & Reddy, E. P. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20220 · Cited by 39
SU2C Phase Ib Study of Paclitaxel and MK-2206 in Advanced Solid Tumors and Metastatic Breast Cancer
Gonzalez-Angulo, A. M., Krop, I. E., Akçakanat, A., Chen, H., Liu, S., Li, Y., Culotta, K. S., Tarco, E., Piha-Paul, S. A., Moulder-Thompson, S. L., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju493 · Cited by 39
Biological and clinical significance of cancer stem cell plasticity
Zhu, Y., Luo, M., Brooks, M. D., Clouthier, S. G., & Wicha, M. S. (2014) · Clinical and Translational Medicine · doi:10.1186/s40169-014-0032-3 · Cited by 39
The voltage gated Ca2+-channel Cav3.2 and therapeutic responses in breast cancer
Pera, E., Kaemmerer, E., Milevskiy, M. J. G., Yapa, K. T. D. S., O’Donnell, J. S., Brown, M. A., Simpson, F., Peters, A. A., Roberts‐Thomson, S. J., & Monteith, G. R. (2016) · Cancer Cell International · doi:10.1186/s12935-016-0299-0 · Cited by 39
TGF-β induces phosphorylation of phosphatase and tensin homolog: implications for fibrosis of the trabecular meshwork tissue in glaucoma
Tellios, N., Belrose, J. C., Tokarewicz, A. C., Hutnik, C. M. L., Liu, H., Leask, A., Motolko, M. A., Iijima, M., & Parapuram, S. K. (2017) · Scientific Reports · doi:10.1038/s41598-017-00845-x · Cited by 39
Phosphatase and tensin homolog (PTEN) expression on oncologic outcome in renal cell carcinoma: A systematic review and meta-analysis
Tang, L., Li, X., Gao, Y., Chen, L., Gu, L., Chen, J., Lyu, X., Zhang, Y., & Zhang, X. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179437 · Cited by 39
Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer
Wen, W. X., Marcinkowski, E., Luyimbazi, D. T., Luu, T. H., Xing, Q., Yan, J., Wang, Y., Wu, J., Guo, Y., Tully, D. S., et al. (2019) · Cells · doi:10.3390/cells8091010 · Cited by 38
New insights into affinity proteins for HER2-targeted therapy: Beyond trastuzumab
Akbari, V., Chou, C.-H. P., & Abedi, D. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188448 · Cited by 39
Cancer Stem Cell-Targeted Therapeutic Approaches for Overcoming Trastuzumab Resistance in HER2-Positive Breast Cancer
Qiu, Y., Yang, L., Liu, H., & Luo, X. (2021) · Stem Cells · doi:10.1002/stem.3381 · Cited by 41
Discovery of potential HER2 inhibitors from Mangifera indica for the treatment of HER2-Positive breast cancer: an integrated computational approach
Balogun, T. A., Iqbal, M. N., Saibu, O. A., Akintubosun, M. O., Lateef, O. M., Nneka, U. C., Abdullateef, O. T., & Omoboyowa, D. A. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1975570 · Cited by 41
Intrinsic Resistance to Chemotherapy in Breast Cancer
Moulder, S. (2010) · Women s Health · doi:10.2217/whe.10.60 · Cited by 39
EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma
Sundvall, M., Karrila, A., Nordberg, J., Grenman, R. A., & Elenius, K. (2010) · Expert Opinion on Emerging Drugs · doi:10.1517/14728211003716442 · Cited by 39
Human Bone Marrow Activates the Akt Pathway in Metastatic Prostate Cells through Transactivation of the α-Platelet–Derived Growth Factor Receptor
Dolloff, N. G., Russell, M. R., Loizos, N., & Fatatis, A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2593 · Cited by 39
Dominant mechanisms of primary resistance differ from dominant mechanisms of secondary resistance to targeted therapies
Asić, K. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.08.004 · Cited by 38
Buparlisib, an oral pan-PI3K inhibitor for the treatment of breast cancer
Geuna, E., Milani, A., Martinello, R., Aversa, C., Valabrega, G., Scaltriti, M., & Montemurro, F. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1008132 · Cited by 39
Loss of lkb1 Expression Reduces the Latency of ErbB2-Mediated Mammary Gland Tumorigenesis, Promoting Changes in Metabolic Pathways
Andrade-Vieira, R., Xu, Z., Colp, P., & Marignani, P. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056567 · Cited by 38
PTEN Deficiency as a Predictive Biomarker of Resistance to HER2-Targeted Therapy in Advanced Gastric Cancer
Zhang, X., Park, J. S., Park, K. H., Kim, K. H., Jung, M., Chung, H. C., Rha, S. Y., & Kim, H. S. (2014) · Oncology · doi:10.1159/000366426 · Cited by 38
Stromal Fibroblasts and the Immune Microenvironment: Partners in Mammary Gland Biology and Pathology?
Unsworth, A., Anderson, R. L., & Britt, K. L. (2014) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-014-9326-8 · Cited by 40
A pathway-based approach for identifying biomarkers of tumor progression to trastuzumab-resistant breast cancer
Nam, S., Chang, H. R., Jung, H. R., Gim, Y., Kim, N. Y., Grailhe, R., Seo, H. R., Park, H. S., Balch, C., Lee, J., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.10.038 · Cited by 38
Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings
Leech, A. O., Vellanki, S. H., Rutherford, E. J., Keogh, A., Jahns, H., Hudson, L., O’Donovan, N., Sabri, S., Abdulkarim, B., Sheehan, K. M., et al. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-1064-1 · Cited by 38
Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma
Leblanc, O., Vacher, S., Lecerf, C., Jeannot, E., Klijanienko, J., Berger, F., Hoffmann, C., Calugaru, V., Badois, N., Chilles, A., et al. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2019.0153 · Cited by 38
HER2 splice variants in breast cancer: investigating their impact on diagnosis and treatment outcomes
Hart, V., Gautrey, H., Kirby, J. A., & Tyson-Capper, A. J. (2020) · Oncotarget · doi:10.18632/oncotarget.27789 · Cited by 41
Amphiregulin confers trastuzumab resistance via AKT and ERK activation in HER2-positive breast cancer
Kim, J., Kim, D. K., Min, A., Lee, K.-H., Nam, H.-J., Kim, J. H., Kim, J.-S., Kim, T., Im, S., & Park, I. A. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-015-2012-4 · Cited by 38
Modeling therapy resistance in genetically engineered mouse cancer models
Rottenberg, S., & Jonkers, J. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2007.11.002 · Cited by 38
La cellule souche cancéreuse
Ginestier, C., Körkaya, H., Dontu, G., Birnbaum, D., Wicha, M. S., & Charafe‐Jauffret, E. (2007) · médecine/sciences · doi:10.1051/medsci/200723121133 · Cited by 50
PI3K Inhibition Overcomes Trastuzumab Resistance: Blockade of ErbB2/ErbB3 Is Not Always Enough
Hynes, N. E., & Dey, J. H. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.04.004 · Cited by 38
Activity and resistance of trastuzumab according to different clinical settings
Tagliabue, E., Campiglio, M., Pupa, S. M., Ménard, S., & Balsari, A. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.06.002 · Cited by 37
CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer
Esteva, F. J., Wang, J., Lin, F., Mejia, J. A., Yan, K., Altundağ, K., Valero, V., Buzdar, A. U., Hortobágyi, G. N., Symmans, W. F., et al. (2007) · Breast Cancer Research · doi:10.1186/bcr1836 · Cited by 38
The evolution of treatment strategies: Aiming at the target
Dinh, P., Sotiriou, C. P., & Piccart, M. J. (2007) · The Breast · doi:10.1016/j.breast.2007.07.032 · Cited by 38
Effect of γ-Linolenic Acid on the Transcriptional Activity of the Her-2/neu (erbB-2) Oncogene
Menéndez, J. A., Vellón, L., Colomer, R., & Lupu, R. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji343 · Cited by 38
Pharmacokinetics, Clinical Indications, and Resistance Mechanisms in Molecular Targeted Therapies in Cancer
Izar, B., Rotow, J. K., Gainor, J. F., Clark, J. W., & Chabner, B. A. (2013) · Pharmacological Reviews · doi:10.1124/pr.113.007807 · Cited by 38
High Expression of Mammalian Target of Rapamycin Is Associated with Better Outcome for Patients with Early Stage Lung Adenocarcinoma
Anagnostou, V., Bepler, G., Syrigos, K. N., Tanoue, L. T., Gettinger, S. N., Homer, R., Boffa, D. J., Detterbeck, F. C., & Rimm, D. L. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0099 · Cited by 37
Blockade of the HER Family of Receptors in the Treatment of HER2-Positive Metastatic Breast Cancer
Sachdev, J. C., & Jahanzeb, M. (2011) · Clinical Breast Cancer · doi:10.1016/j.clbc.2011.07.001 · Cited by 37
Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2‐positive metastatic breast cancer
Murthy, R. K., Varma, A., Mishra, P., Hess, K. R., Young, E. J., Murray, J. L., Koenig, K. H., Moulder, S. L., Melhem‐Bertrandt, A., Giordano, S. H., et al. (2014) · Cancer · doi:10.1002/cncr.28689 · Cited by 37
Label-Free Quantitative Proteomics Combined with Biological Validation Reveals Activation of Wnt/β-Catenin Pathway Contributing to Trastuzumab Resistance in Gastric Cancer
Liu, W., Yuan, J., Liu, Z., Zhang, J., & Chang, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071981 · Cited by 37
HER2-positive male breast cancer: an update
Ottini, L., Ottini, L., Capalbo, C., Rizzolo, P., Silvestri, V., Rizzo, & Russo (2010) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s6519 · Cited by 37
PTPs emerge as PIPs: protein tyrosine phosphatases with lipid-phosphatase activities in human disease
Pulido, R., Stoker, A. W., & Hendriks, W. J. A. J. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt347 · Cited by 37
Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
Cheng, X., Sun, Y., Highkin, M. K., Vemalapally, N., Jin, X., Zhou, B., Prior, J. L., Tipton, A. R., Li, S., Iliuk, A. B., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3558 · Cited by 38
Somatic alterations as the basis for resistance to targeted therapies
Blair, B. G., Bardelli, A., & Park, B. H. (2013) · The Journal of Pathology · doi:10.1002/path.4278 · Cited by 36
Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models
Crafter, C., VINCENT, J. P., TANG, E. K. Y., Dudley, P., James, N. H., Klinowska, T. C. M., & Davies, B. R. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3062 · Cited by 36
Inhibition of Type I Insulin-Like Growth Factor Receptor Signaling Attenuates the Development of Breast Cancer Brain Metastasis
Saldana, S. M., Lee, H., Lowery, F. J., Khotskaya, Y. B., Xia, W., Zhang, C., Chang, S.-S., Chou, C., Steeg, P. S., Yu, D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073406 · Cited by 36
Cell‐specific biomarkers and targeted biopharmaceuticals for breast cancer treatment
Liu, M., Li, Z., Yang, J., Jiang, Y., Chen, Z., Ali, Z., He, N., & Wang, Z. (2016) · Cell Proliferation · doi:10.1111/cpr.12266 · Cited by 37

Authors: Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., Hortobagyi, G. N., Hung, M.-C., & Yu, D.
Affiliations: The University of Texas MD Anderson Cancer Center (US)
Ionis Pharmaceuticals (United States) (US)
Corresponding author: Yu, Dihua
ORCID: Lan, Keng-Hsueh
Zhou, Xiaoyan
Tan, Ming
Esteva, Francisco J.
Li, Ping
Monia, Brett P.
Hung, Mien-Chie
Yu, Dihua
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2004-08
Volume: 6
Issue: 2
Pages: 117-127
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/j.ccr.2004.06.022
OpenAlex: W2059411043
Cited by: 1,858
References: 70
Citations by year: 2026: 19 · 2025: 29 · 2024: 35 · 2023: 82 · 2022: 52 · 2021: 50 · 2020: 60 · 2019: 56 · 2018: 66 · 2017: 68 · 2016: 88 · 2015: 109 · 2014: 119 · 2013: 125 · 2012: 123
FWCI: 43.34
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 3272 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (5r01ca060488-09)
National Cancer Institute (P01CA099031, 2R01-CA60488, P30CA016672)
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords: PTEN, trastuzumab, trastuzumab resistance, ERBB2, HER2-positive breast cancer, Src kinase inhibition, PI3K inhibitors, predictive biomarkers, antisense oligonucleotides
MeSH terms: Trastuzumab, Phosphoinositide-3 Kinase Inhibitors, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Breast Neoplasms, Enzyme Activation, Enzyme Inhibitors, Female, Humans, Mice, Nude, Neoplasm Transplantation, Phosphoric Monoester Hydrolases, Proto-Oncogene Proteins, Genes, Tumor Suppressor, Oligonucleotides, Antisense, Protein Serine-Threonine Kinases, Erb-b2 Receptor Tyrosine Kinases, Drug Resistance, Neoplasm, src-Family Kinases, Phosphatidylinositol 3-Kinases, Tumor Suppressor Proteins, Cell Line, Tumor, Proto-Oncogene Proteins c-akt, PTEN Phosphohydrolase, Mice, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks